Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 62 points (-0.4%) at 15,060 as of Wednesday, June 12, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 760 issues advancing vs. 2,254 declining with 88 unchanged. The Health Services industry currently sits down 0.10 versus the S&P 500, which is down 0.61. On the negative front, top decliners within the industry include Agilent Technologies ( A), down 0.95, Thermo Fisher Scientific ( TMO), down 0.95 and Catamaran ( CTRX), down 0.70. A company within the industry that increased today was Smith & Nephew ( SNN), up 2.27. TheStreet Ratings group would like to highlight 4 stocks pushing the industry lower today: 4. Ironwood Pharmaceuticals ( IRWD) is one of the companies pushing the Health Services industry lower today. As of noon trading, Ironwood Pharmaceuticals is down $0.57 (-4.5%) to $12.24 on average volume Thus far, 513,858 shares of Ironwood Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $12.16-$13.00 after having opened the day at $12.82 as compared to the previous trading day's close of $12.81. Ironwood Pharmaceuticals, Inc., an entrepreneurial pharmaceutical company, discovers, develops, and commercializes human therapeutic products. Ironwood Pharmaceuticals has a market cap of $1.2 billion and is part of the health care sector. Shares are up 19.2% year to date as of the close of trading on Tuesday. Currently there are 3 analysts that rate Ironwood Pharmaceuticals a buy, 2 analysts rate it a sell, and 5 rate it a hold. TheStreet Ratings rates Ironwood Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income, disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full Ironwood Pharmaceuticals Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.